Organization · Community
HS100
HS100 is a founder-led organization based in Aix-en-Provence, France, focused on extending human healthspan to 100 years and beyond through investment in longevity startups and research. It operates the 2060 Longevity Investment Club, connecting investors with innovative companies in the longevity sector.
Overview
What HS100 does
What HS100 is
HS100 is a founder-led organization based in Aix-en-Provence, France, focused on extending human healthspan to 100 years and beyond through investment in longevity startups and research. It operates the 2060 Longevity Investment Club, connecting investors with innovative companies in the longevity sector.
How it participates in the startup ecosystem
The current public profile supports funder and community capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Community
- Structured capabilities
- Funder · Community
- Last reviewed
- April 26, 2026
Official channels
Find HS100 elsewhere
Open the official website or a supported primary organization account.
Capability profile
HS100 as a funder
Investment thesis
HS100 believes that extending healthspan and defeating aging will become one of the largest scientific and investment opportunities of the coming decades, combining near-term preventative medicine with longer-term R&D and startup investment.
Focus narrative
HS100 invests in the longevity sector, focusing on both short-term preventative medicine and long-term research and development of innovative technologies. Through initiatives like the 2060 Longevity Investment Club, HS100 connects investors with promising longevity startups, believing that significant breakthroughs in aging science are imminent and that funding is crucial to accelerate these developments.
Value beyond capital
HS100 provides access to a community of investors, deal-flow aggregation, diligence, events, and co-investment opportunities through the 2060 Longevity Club, enhancing the potential for portfolio companies to secure funding and grow.
Terms and economics
- Typical check
- $1,000
Focus and fit
- Stages
- Friends and Family · Angel · Accelerator · Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity
- Sectors
- Longevity · Biotech · Healthcare · Senolytics
- Regions
- Global · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 5
Portfolio context
BE Therapeutics: Focused on brain tissue engineering and replacement. Etheros Pharmaceuticals: Developing drugs to combat age-related cognitive decline. Starkage Therapeutics: Specializing in senolytics. Vincere Biosciences: Working on mitochondria rejuvenation. Ikare: A concierge medicine service aimed at promoting longer, healthier lives.
Capability profile
HS100 as a community
Community overview
HS100 is an organization dedicated to extending human healthspan to 100 years and beyond. Founded by Gabriel Cian, a tech entrepreneur with a background in software engineering, HS100 is based in Aix-en-Provence, France. The organization aims to create a comprehensive ecosystem that supports research and development in longevity, advocating for the recognition of aging as a disease that can be cured.
Community focus
HS100 invests in the longevity sector, emphasizing both short-term preventative medicine and long-term research and development of innovative technologies. The organization operates through initiatives such as the 2060 Longevity Investment Club, which connects investors with promising longevity startups. Their investment thesis is centered on the belief that significant breakthroughs in aging science are imminent and that funding is crucial to accelerate these developments.
Member value
Members of HS100 gain access to a community of investors dedicated to funding high-potential longevity startups. They can participate in the 2060 Longevity Investment Club, receive insights through the HS100 Newsletter, and engage in events like the 2060 Longevity Forum, which gathers leaders in the longevity field to discuss investment opportunities and advancements.
Membership
- Membership fee
- $5,000 · one-time
- Pricing models
- fixed-tuition
Format and cadence
- Modality
- in-person
- Schedule
- rolling-admissions
- Commitment
- light
Availability
- Membership state
- Accepting
- Next recorded event
- August 30, 2025
Audience and fit
- Audience
- Founders · Investors
- Benefits
- network-access
- Program types
- community
- Selection criteria
- open
- Stages
- Seed · Seed+
- Regions
- Global · Europe
Community activity
Events and activity
The 2060 Longevity Forum is scheduled for August 30-31, 2025, in Aix-en-Provence, France. This event will feature over 50 participants, including investors and scientists, and aims to establish a global dialogue on longevity as an investment thesis.
Notable members
Notable companies associated with HS100 include BE Therapeutics, Etheros Pharmaceuticals, Starkage Therapeutics, Vincere Biosciences, and Ikare.
Common questions
What to know about HS100
Upseed classifies HS100 under the Community organization type. Its current public profile includes funder and community capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.